Elsevier

Neuroscience Letters

Volume 212, Issue 2, 12 July 1996, Pages 91-94
Neuroscience Letters

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease

https://doi.org/10.1016/0304-3940(96)12774-9Get rights and content

Abstract

Apolipoprotein E (Apo E), one of the major structural and functional apolipoproteins, has recently been implicated in the pathogenesis of Alzheimer's disease (AD). Several studies revealed that Apo E4 isoform is associated with the pathogenic process in AD. A significant reduction of cerebrospinal fluid (CSF) Apo E level in AD patients has been reported in two studies. To further investigate the physiopathological significance of such a variation of Apo E concentration in the CSF, we performed a quantification of Apo E by an enzyme linked immunosorbent assay (ELISA). There were no significant differences in CSF Apo E level between AD cases and control subjects or patients suffering from other neurological diseases. Gender, age and Apo E phenotype explained none of CSF Apo E concentration variability.

References (23)

  • T. Lehtimäki et al.

    Apolipoproteint E (Apo E) polymorphism and its influence on Apo E concentration in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

    Hum. Genet.

    (1995)
  • Cited by (44)

    • An ultrasensitive electrochemical immunosensor for apolipoprotein E4 based on fractal nanostructures and enzyme amplification

      2015, Biosensors and Bioelectronics
      Citation Excerpt :

      The detection limit for human APOE4 based on the FracAu electrochemical immunosensor is 0.3 ng/mL (S/N=3, Fig. 4C red line). In physiological conditions, the concentration of APOE4 is typically in the μg/mL range for cerebrospinal fluid (CSF) in the individuals that do have APOE4 allele (Lefranc et al., 1996). Hence, the detection limit of the as-fabricated electrochemical immunosensor can meet the requirements of clinical application.

    • Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): A pilot assay for methionine-containing proteotypic peptides

      2012, Molecular and Cellular Proteomics
      Citation Excerpt :

      The same influencing order is found for brain amyloid β accumulation across cognitively normal individuals as demonstrated by imaging studies (82–85). Thus, a large body of evidence converges on a pivotal role of ApoE in the neurodegeneration process associated with a possible disruption of ApoE levels in the cerebrospinal fluid (7, 86–95). This is reinforced by the recent article by Cramer et al. who demonstrated reduced Aβ plaque area and improved cognitive functions in a mouse model of AD after treatment by bexarotene, an agonist of nuclear receptors that transcriptionally regulates ApoE expression (96).

    • Cerebrospinal fluid apolipoprotein e levels in subacute sclerosing panencephalitis

      2012, Brain and Development
      Citation Excerpt :

      Experimental studies have shown that Apo E influences the majority of the pathological processes of AD, including amyloid-beta (Ab) deposition and tangle formation [6]. Although ApoE takes part in the pathogenesis of AD disease, cerebrospinal fluid Apo E levels are not significantly changed in AD compared to control subjects [7,8]. Apo E may be involved in the pathogenesis of subacute sclerosing panencephalitis (SSPE), a persistent infection of the central nervous system (CNS) characterized by a subacute inflammatory process and degenerative changes including perivascular lymphocytic infiltrates, neuronal loss, demyelinization, and neuronal inclusion bodies [9].

    • Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples

      2010, Molecular and Cellular Proteomics
      Citation Excerpt :

      Here we examined well-defined CSF samples obtained from patients who did not have neurological disorders and we found profound differences in protein abundances between individuals. Characterization of variation of CSF levels of amyloid beta (33) and apolipoprotein E (34) in patients who have Alzheimer's disease have been published, but this is the first attempt to characterize a large number of proteins in CSF of patients who do not have neurological afflictions. Some proteins, such as serotransferrin and fibulin-1, appear to be more constant than others with regards to abundance levels in CSF, as these showed only limited variations in both the sample set of nine non-neurological individuals and the validation set as well as in the experimental sample set.

    View all citing articles on Scopus

    This work was supported by a grant from the Conseil Régional du Nord-Pas-de-Calais and the CHR&U of Lille.

    View full text